ECSP19046893A - Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip - Google Patents
Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gipInfo
- Publication number
- ECSP19046893A ECSP19046893A ECSENADI201946893A ECDI201946893A ECSP19046893A EC SP19046893 A ECSP19046893 A EC SP19046893A EC SENADI201946893 A ECSENADI201946893 A EC SENADI201946893A EC DI201946893 A ECDI201946893 A EC DI201946893A EC SP19046893 A ECSP19046893 A EC SP19046893A
- Authority
- EC
- Ecuador
- Prior art keywords
- glucagon
- trigonal
- glp1
- new compounds
- gip receptors
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 3
- 229960004666 glucagon Drugs 0.000 title abstract 3
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 108060003199 Glucagon Proteins 0.000 title 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Nuevos compuestos como agonistas peptídicos trigonales de los receptores de GLP1/Glucagón/GIP La presente invención se refiere a agonistas trigonales de los receptores de GLP-1 / glucagón / GIP y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, incluyendo diabetes y obesidad, así como para la reducción del exceso de ingesta de alimentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306604 | 2016-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19046893A true ECSP19046893A (es) | 2019-07-31 |
Family
ID=57542935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201946893A ECSP19046893A (es) | 2016-12-02 | 2019-07-01 | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10538567B2 (es) |
| EP (1) | EP3548508B1 (es) |
| JP (1) | JP7100033B2 (es) |
| KR (1) | KR102576872B1 (es) |
| CN (1) | CN110023329B (es) |
| AR (1) | AR110300A1 (es) |
| AU (1) | AU2017367173B2 (es) |
| BR (1) | BR112019011228A2 (es) |
| CA (1) | CA3045377A1 (es) |
| CL (1) | CL2019001465A1 (es) |
| CO (1) | CO2019006917A2 (es) |
| CR (1) | CR20190313A (es) |
| DO (1) | DOP2019000068A (es) |
| EA (1) | EA201991345A1 (es) |
| EC (1) | ECSP19046893A (es) |
| IL (1) | IL266984A (es) |
| MA (1) | MA46955A (es) |
| MX (1) | MX2019006429A (es) |
| PE (1) | PE20191143A1 (es) |
| PH (1) | PH12019501216A1 (es) |
| TW (1) | TW201833132A (es) |
| UY (1) | UY37506A (es) |
| WO (1) | WO2018100134A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| KR102793451B1 (ko) | 2018-04-10 | 2025-04-11 | 사노피-아벤티스 도이칠란트 게엠베하 | 고체상으로부터 고체상-결합된 펩타이드를 절단하는 방법 |
| BR112020020647A2 (pt) | 2018-04-10 | 2021-02-23 | Sanofi-Aventis Deutschland Gmbh | síntese de lixisenatida com capeamento |
| TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物 |
| KR20200078413A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 |
| CA3138715A1 (en) | 2019-06-14 | 2020-12-17 | Zealand Pharma A/S | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| CN114786706A (zh) * | 2019-10-04 | 2022-07-22 | 韩美药品株式会社 | 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途 |
| PE20221168A1 (es) | 2019-11-11 | 2022-07-25 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| TW202228762A (zh) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| EP4197550A4 (en) * | 2020-08-14 | 2025-10-08 | Hanmi Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS |
| CN114349828B (zh) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | Glp-1/胰高血糖素受体双重激动剂及其应用 |
| JP7751641B2 (ja) * | 2020-12-16 | 2025-10-08 | ジーランド ファーマ エー／エス | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 |
| EP4262745B1 (en) * | 2020-12-16 | 2025-01-29 | Zealand Pharma A/S | Pharmaceutical composition of glp-1/glp-2 dual agonists |
| AU2022298632A1 (en) * | 2021-06-25 | 2023-12-14 | Eli Lilly And Company | Methods for treating obstructive sleep apnea |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| AU2023276018A1 (en) * | 2022-05-27 | 2024-11-21 | D&D Pharmatech Inc. | Peptide compositions and methods of use threof |
| EP4596574A1 (en) * | 2022-09-28 | 2025-08-06 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg/gip triple-receptor agonist and use thereof |
| AU2023408167B2 (en) * | 2022-12-23 | 2025-09-04 | Hanmi Pharm. Co., Ltd. | Novel triple GLP-1/GIP/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same |
| WO2025049610A1 (en) * | 2023-08-28 | 2025-03-06 | Shattuck Labs, Inc. | Multi-action peptides |
| CN117586374B (zh) * | 2023-10-07 | 2024-11-29 | 深圳湾实验室 | Glp-1r/gipr/gcgr三重激动剂类似物及其用途 |
| CN119241684B (zh) * | 2024-11-22 | 2025-02-25 | 徐州医科大学 | 一种肠促胰岛素类似物及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL377591A1 (pl) | 2002-10-02 | 2006-02-06 | Zealand Pharma A/S | Stabilizowane związki eksendyny-4 |
| US20080019911A1 (en) * | 2005-04-20 | 2008-01-24 | Aimin Xu | Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4 |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| CA2821766A1 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| JP6300239B2 (ja) | 2012-06-21 | 2018-03-28 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| EP3080151A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
-
2017
- 2017-11-30 AR ARP170103362A patent/AR110300A1/es unknown
- 2017-11-30 TW TW106141759A patent/TW201833132A/zh unknown
- 2017-12-01 MA MA046955A patent/MA46955A/fr unknown
- 2017-12-01 MX MX2019006429A patent/MX2019006429A/es unknown
- 2017-12-01 CN CN201780074707.9A patent/CN110023329B/zh active Active
- 2017-12-01 EP EP17821804.6A patent/EP3548508B1/en active Active
- 2017-12-01 JP JP2019529535A patent/JP7100033B2/ja active Active
- 2017-12-01 WO PCT/EP2017/081125 patent/WO2018100134A1/en not_active Ceased
- 2017-12-01 UY UY0001037506A patent/UY37506A/es unknown
- 2017-12-01 AU AU2017367173A patent/AU2017367173B2/en active Active
- 2017-12-01 US US15/829,680 patent/US10538567B2/en active Active
- 2017-12-01 CR CR20190313A patent/CR20190313A/es unknown
- 2017-12-01 EA EA201991345A patent/EA201991345A1/ru unknown
- 2017-12-01 BR BR112019011228A patent/BR112019011228A2/pt not_active Application Discontinuation
- 2017-12-01 PE PE2019000905A patent/PE20191143A1/es unknown
- 2017-12-01 CA CA3045377A patent/CA3045377A1/en not_active Abandoned
- 2017-12-01 KR KR1020197018943A patent/KR102576872B1/ko active Active
-
2019
- 2019-03-19 DO DO2019000068A patent/DOP2019000068A/es unknown
- 2019-05-29 IL IL266984A patent/IL266984A/en unknown
- 2019-05-30 CL CL2019001465A patent/CL2019001465A1/es unknown
- 2019-05-31 PH PH12019501216A patent/PH12019501216A1/en unknown
- 2019-06-27 CO CONC2019/0006917A patent/CO2019006917A2/es unknown
- 2019-07-01 EC ECSENADI201946893A patent/ECSP19046893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019006917A2 (es) | 2019-07-10 |
| EP3548508A1 (en) | 2019-10-09 |
| EP3548508B1 (en) | 2021-10-27 |
| MA46955A (fr) | 2021-05-19 |
| WO2018100134A1 (en) | 2018-06-07 |
| CR20190313A (es) | 2019-09-11 |
| DOP2019000068A (es) | 2019-05-31 |
| EA201991345A1 (ru) | 2019-11-29 |
| BR112019011228A2 (pt) | 2019-10-15 |
| KR20190085141A (ko) | 2019-07-17 |
| AR110300A1 (es) | 2019-03-13 |
| CN110023329A (zh) | 2019-07-16 |
| UY37506A (es) | 2018-06-29 |
| KR102576872B1 (ko) | 2023-09-12 |
| PH12019501216A1 (en) | 2019-08-19 |
| AU2017367173A1 (en) | 2019-07-18 |
| CL2019001465A1 (es) | 2019-10-18 |
| CA3045377A1 (en) | 2018-06-07 |
| MX2019006429A (es) | 2019-08-21 |
| US20180155406A1 (en) | 2018-06-07 |
| IL266984A (en) | 2019-07-31 |
| PE20191143A1 (es) | 2019-09-02 |
| JP7100033B2 (ja) | 2022-07-12 |
| TW201833132A (zh) | 2018-09-16 |
| AU2017367173B2 (en) | 2022-03-24 |
| US10538567B2 (en) | 2020-01-21 |
| JP2019536796A (ja) | 2019-12-19 |
| CN110023329B (zh) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19046893A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| BR112019011144A2 (pt) | compostos como agonistas peptídicos de receptor de glp1/glucagon/gip | |
| AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
| UY35231A (es) | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón | |
| BR112016022754A2 (pt) | derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| UY35072A (es) | Derivados de exendina-4 como agonistas duales de GLP1/glucagón | |
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| BR112016023039A2 (pt) | agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4 | |
| CO7400885A2 (es) | Análogos de glucagón | |
| GT201500049A (es) | Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| GT201500168A (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
| CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
| CR20170470A (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) | |
| ECSP15009978A (es) | Análogos de glucagón |